Robert Whalen

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Altravax, Inc. discovers and develops new vaccines to fight infectious diseases. The firm’s proprietary technologies offer unique opportunities to create novel vaccine or improve currently available alternatives to fill unmet medical needs. It provides contract services. It has a robust pipeline of candidates at various stages of development. The company was founded by Sean X. Du and Robert Whalen in 2009 and is headquartered in Sunnyvale, CA.